Physician profile
Mukund Kumar
NPI 1659896694
$784.33
in general payments reported to CMS, 2019-2025
14 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.65 · 2022: $106 · 2023: $264 · 2024: $240 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $209.52 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $138.60 | 2023-2025 | |
| Janssen Biotech, INC. | $90.84 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $69.70 | 2023-2025 | |
| Abbott Laboratories | $44.27 | 2023-2024 | Proclaim |
| Genzyme Corporation | $37.54 | 2025 | |
| Mallinckrodt Hospital Products INC. | $35.18 | 2024-2025 | Acthar |
| Kyowa Kirin, INC. | $30.79 | 2023-2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $30.71 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $23.55 | 2023 | Lupkynis |
| Organon LLC | $20.07 | 2023 | |
| Ucb, INC. | $19.18 | 2024 | Cimzia |
| Pfizer INC. | $18.65 | 2019 | |
| Genentech USA, INC. | $15.73 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukund Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.